BG
KYMR icon

Bellevue Group’s Kymera Therapeutics KYMR Stock Holding History

Bellevue Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52,400
Closed -$2.22M – 178
2022
Q1 		$2.22M Buy
52,400
+3,400
+7% +$144K 0.03% 132
2021
Q4 		$3.11M Buy
49,000
+13,500
+38% +$786K 0.03% 137
2021
Q3 		$2.08M Buy
+35,500
New +$2.06M 0.02% 147

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bellevue Group's KYMR Position: Q2 2022 in Review

Bellevue Group sold out of Kymera Therapeutics (KYMR) in Q2 2022, closing a stake of 52,400 shares — an estimated $2.22M sold.

Bellevue Group first reported a position in KYMR in Q3 2021 and held it in 3 quarters. The position peaked at $3.11M in Q4 2021. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2022.

  • Bellevue Group reported no remaining Kymera Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bellevue Group sold 52,400 Kymera Therapeutics shares in Q2 2022, an estimated $2.22M.
  • Bellevue Group first reported a position in Kymera Therapeutics in Q3 2021 and held it in 3 quarters.
  • Bellevue Group's Kymera Therapeutics position peaked at $3.11M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2022.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.